Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN program priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA requests public comment on the center's year 2000 program priorities in a Sept. 1 Federal Register. The deadline for comments is Sept. 30. FDA intends to make the new workplan public in January. The center continues work on its 1999 strategic plan "A-List" priorities, including resolution of issues involving ephedra-containing supplements, prompt review of new dietary ingredients, implementation of the authoritative statement provision of the FDA Modernization Act, development of an overall strategy on dietary supplements and issues involving third-party literature (1"The Tan Sheet" Feb. 1, p. 9). In July, CFSAN added to its "A List" development of a response strategy to the federal appeals court decision in Pearson v. Shalala (2"The Tan Sheet" July 12, In Brief)
Advertisement

Related Content

CFSAN program priorities
CFSAN Strategic Plan Focuses On Ephedra, Nutrient Content/Health Claims
CFSAN Strategic Plan Focuses On Ephedra, Nutrient Content/Health Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS090273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel